P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Extending the Bacillus cereus group genomics to putative food-borne pathogens of different toxicity.
Alla Lapidus,Eugene Goltsman,Sandrine Auger,Nathalie Galleron,Béatrice Segurens,Carole Dossat,Miriam Land,Véronique Broussolle,Julien Brillard,Marie-Hélène Guinebretière,Vincent Sanchis,Christophe Nguen-the,Didier Lereclus,Paul G. Richardson,Patrick Wincker,Jean Weissenbach,S. Dusko Ehrlich,Alexei Sorokin +17 more
TL;DR: The preliminary analysis of the sequences of three genomes discussed in this paper narrows down the gaps in knowledge of the B. cereus group and incite to consider a necessity of creating prophylactic vaccines against bacteria closely related to NVH391-98 and F837/76.
Journal ArticleDOI
Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma
Martha Q. Lacy,Melissa Alsina,Rafael Fonseca,M. Luisa Paccagnella,Carrie Lynn Melvin,Donghua Yin,Amarnath Sharma,M. Enriquez Sarano,Michael Pollak,Sundar Jagannath,Paul G. Richardson,Antonio Gualberto +11 more
TL;DR: Data indicate that CP-751,871 is well tolerated and may constitute a novel agent in the treatment of multiple myeloma.
Journal ArticleDOI
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)
Dharminder Chauhan,Paola Neri,Mugdha Velankar,Klaus Podar,Teru Hideshima,Mariateresa Fulciniti,Pierfrancesco Tassone,Noopur Raje,Constantine S. Mitsiades,Nicholas Mitsiades,Paul G. Richardson,Leigh Zawel,Mary Ann Tran,Nikhil C. Munshi,Kenneth C. Anderson +14 more
TL;DR: Combining LBW242 with novel agents, including tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or the proteasome inhibitors bortezomib and NPI-0052, as well as with the conventional anti-MM agent melphalan, induces additive/synergisticAnti-MM activity.
Journal ArticleDOI
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
Paul G. Richardson,David S. Siegel,Rachid Baz,Susan L. Kelley,Nikhil C. Munshi,Jacob P. Laubach,Daniel C. Sullivan,Melissa Alsina,Robert L. Schlossman,Irene M. Ghobrial,Deborah Doss,Nora Loughney,Laura McBride,Elizabeth Bilotti,Palka Anand,Lisa A. Nardelli,Sandra Wear,Gail Larkins,Min Chen,M. Zaki,Christian Jacques,Kenneth C. Anderson +21 more
TL;DR: Pomalidomide 4 mg per day on days 1 to 21 of each 28-day cycle, with or without dexamethasone (40 mg/week), has encouraging activity with manageable toxicity in RRMM, including those refractory to both lenalidomides and bortezomib.
Journal ArticleDOI
Complete Genome Sequence of the Complex Carbohydrate-Degrading Marine Bacterium, Saccharophagus degradans Strain 2-40T
Ronald M. Weiner,Larry E. Taylor,Bernard Henrissat,Loren Hauser,Miriam Land,Pedro M. Coutinho,Corinne Rancurel,Elizabeth Saunders,Atkinson G. Longmire,Haitao Zhang,Edward A. Bayer,Harry J. Gilbert,Frank W. Larimer,Igor B. Zhulin,Nathan A. Ekborg,Raphael Lamed,Paul G. Richardson,Ilya Borovok,Steven W. Hutcheson +18 more
TL;DR: This is the first sequenced genome of a marine bacterium that can degrade plant cell walls, an important component of the carbon cycle that is not well-characterized in the marine environment.